ATE492277T1 - Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n-4-methyl-3-( -(pyridin-3-yl)pyrimidin-2- ylamino)phenyl-benzamid zur hemmung des tyrosinkinaserezeptors c-fms - Google Patents

Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n-4-methyl-3-( -(pyridin-3-yl)pyrimidin-2- ylamino)phenyl-benzamid zur hemmung des tyrosinkinaserezeptors c-fms

Info

Publication number
ATE492277T1
ATE492277T1 AT05793868T AT05793868T ATE492277T1 AT E492277 T1 ATE492277 T1 AT E492277T1 AT 05793868 T AT05793868 T AT 05793868T AT 05793868 T AT05793868 T AT 05793868T AT E492277 T1 ATE492277 T1 AT E492277T1
Authority
AT
Austria
Prior art keywords
fms
ylamino
benzamide
ylmethyl
phenyl
Prior art date
Application number
AT05793868T
Other languages
English (en)
Inventor
Andrea Dewar
Timothy Hughes
Alan Lyons
Original Assignee
Medvet Science Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medvet Science Pty Ltd filed Critical Medvet Science Pty Ltd
Application granted granted Critical
Publication of ATE492277T1 publication Critical patent/ATE492277T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT05793868T 2004-10-18 2005-10-17 Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n-4-methyl-3-( -(pyridin-3-yl)pyrimidin-2- ylamino)phenyl-benzamid zur hemmung des tyrosinkinaserezeptors c-fms ATE492277T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61974404P 2004-10-18 2004-10-18
PCT/AU2005/001602 WO2006042362A1 (en) 2004-10-18 2005-10-17 Use of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms

Publications (1)

Publication Number Publication Date
ATE492277T1 true ATE492277T1 (de) 2011-01-15

Family

ID=36202610

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05793868T ATE492277T1 (de) 2004-10-18 2005-10-17 Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n-4-methyl-3-( -(pyridin-3-yl)pyrimidin-2- ylamino)phenyl-benzamid zur hemmung des tyrosinkinaserezeptors c-fms

Country Status (19)

Country Link
US (1) US20080255139A1 (de)
EP (1) EP1804800B1 (de)
JP (1) JP2008516898A (de)
KR (1) KR20070083705A (de)
CN (1) CN101035535A (de)
AT (1) ATE492277T1 (de)
AU (1) AU2005297321A1 (de)
BR (1) BRPI0517083A (de)
CA (1) CA2580976A1 (de)
DE (1) DE602005025514D1 (de)
IL (1) IL182419A0 (de)
MA (1) MA28946B1 (de)
MX (1) MX2007004660A (de)
NO (1) NO20072501L (de)
NZ (1) NZ554009A (de)
RU (1) RU2007118420A (de)
TN (1) TNSN07141A1 (de)
WO (1) WO2006042362A1 (de)
ZA (1) ZA200702316B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008318656A1 (en) * 2007-10-31 2009-05-07 Janssen Pharmaceutica N.V. Biomarker for assessing response to FMS treatment
EP3246046A4 (de) * 2015-01-13 2018-12-05 Kyoto University Mittel zur prävention und/oder behandlung von amyotropher lateralsklerose

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837237A (en) * 1985-07-09 1989-06-06 Fred Hutchinson Cancer Research Center Therapy using glucosidase processing inhibitors
CA2446939C (en) * 2001-05-16 2005-08-02 Matthias Stein-Gerlach Pyridylpyrimidine derivatives as effective compounds against prion diseases
WO2004026930A2 (en) * 2002-06-26 2004-04-01 The Ohio State University Research Foundation The method for reducing inflammation using sti-571 or its salt

Also Published As

Publication number Publication date
RU2007118420A (ru) 2008-11-27
MX2007004660A (es) 2007-10-17
TNSN07141A1 (en) 2008-11-21
KR20070083705A (ko) 2007-08-24
DE602005025514D1 (de) 2011-02-03
EP1804800A4 (de) 2008-03-19
IL182419A0 (en) 2007-09-20
US20080255139A1 (en) 2008-10-16
CA2580976A1 (en) 2006-04-27
EP1804800A1 (de) 2007-07-11
WO2006042362A1 (en) 2006-04-27
MA28946B1 (fr) 2007-10-01
ZA200702316B (en) 2008-09-25
AU2005297321A1 (en) 2006-04-27
NO20072501L (no) 2007-05-15
CN101035535A (zh) 2007-09-12
EP1804800B1 (de) 2010-12-22
JP2008516898A (ja) 2008-05-22
BRPI0517083A (pt) 2008-09-30
NZ554009A (en) 2010-09-30

Similar Documents

Publication Publication Date Title
PT1332137E (pt) Tratamento de tumores estromais gastrintestinais
PE20121476A1 (es) Composicion para el tratamiento de trastornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r
PE20120626A1 (es) Composiciones farmaceuticas que comprende nilotinib
NO20075624L (no) Nye histamin H3-reseptorligander og deres terapeutiske anvendelser
MY148375A (en) Delta and epsilon crystal forms of imatinib mesylate
HUE034712T2 (hu) Amidszármazék és gyógyszer
TWI347186B (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
MY148878A (en) Stabilized amorphous forms of imatinib mesylate
IL201790A0 (en) Pyridyl piperidine orexin receptor antagonists
NO20075022L (no) (7-(2-(4-(3-trifluormetylfenyl)-1,2,3,6-tetrahydropyrid-1-yl)etyl) isokinolinbesylatsalt, fremstilling og terapeutiske anvendelser derav
EA201070366A1 (ru) 3-метил-2-((2s)-2-(4-(3-метил-1,2,4-оксадиазол-5-ил)фенил)морфолино)-6-(пиримидин-4-ил)пиримидин-4(3н)-он в качестве ингибитора тау-протеинкиназы
WO2008059551A3 (en) Process for the preparation of imatinib and intermediates thereof
ATE542814T1 (de) Pyrazinkinaseinhibitoren
NZ590177A (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
MY146403A (en) F, g, h, i and k crystal forms of imatinib mesylate
PE20141337A1 (es) Formulacion de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida
IL182419A0 (en) Use of 4- (4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms
IL162983A (en) Use of imatinib for the manufacture of pharmaceutical compositions for the treatment of rheumatoid arthritis
ES2421587T3 (es) Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica
HRP20100265T1 (hr) Smjesa od pirimidilaminobenzamid spojeva i imatiniba za liječenje ili prevenciju proliferativnih bolesti
JP2008542390A5 (de)
IL171927A0 (en) Use of tyrosine kinase inhibitor to treat diabetes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties